Trial Profile

A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venetoclax (Primary) ; Azacitidine; Blood mononuclear cell therapy; Busulfan; Cedazuridine/decitabine; Fludarabine; Methotrexate; Tacrolimus
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions

20 May 2026 Planned End Date changed from 1 Mar 2027 to 5 Mar 2030.
24 Dec 2025 Planned End Date changed from 1 Feb 2026 to 1 Mar 2027.
24 Dec 2025 Planned primary completion date changed from 1 Dec 2025 to 1 May 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com